Cardiff's__O research__O on__O chronic__O inflammatory__O diseases__O has__O had__O a__O direct__O economic__O impact__O on__O major__O global__O manufacturers__O of__O health__O supplements__O and__O pet__O foods__O (total__O global__O markets__O worth__O $142bn5.1__O and__O $58bn5.2,__O respectively__O in__O 2011)__O through:__O contributing__O to__O the__O development__O of__O new__O products__O containing__O omega-3,__O and__O providing__O a__O credible__O scientific__O basis__O for__O successful__O marketing__O campaigns__O for__O these__O products,__O based__O on__O their__O beneficial__O anti-inflammatory__O effects.__O
Further__O economic__O benefit__O has__O been__O gained__O through__O the__O commercialisation__O of__O neoepitope__O mAbs__O developed__O at__O Cardiff__B-LOC through__O direct__O sales__O and__O licensing__O agreements__O with__O major__O pharmaceutical__O companies.__O
Patent__O driven__O Sales__O of__O Pet__B-LOC Food.__I-LOC
Cardiff__B-LOC performed__O in__O vitro__O research__O in__O collaboration__O with__O Hill's__B-ORG Pet__I-ORG Nutrition,__I-ORG Inc,__I-ORG a__O subsidiary__O of__O the__O Colgate-Palmolive__B-MISC group__O (a__B-ORG Fortune__I-ORG 200__O company).__O
Specifically,__O the__O three__O principal__O omega-3__O PUFAs__B-ORG found__O in__O fish__O oil__O were__O tested__O using__O the__O biochemical__O readouts__O developed__O at__O Cardiff__B-ORG (Section__I-ORG 2)__O in__O collaboration__O with__O researchers__O from__O Liverpool__B-ORG University__I-ORG who__O performed__O clinical__O trials__O (Vet__B-ORG School).__I-ORG
The__O director__O of__O Professional__B-ORG and__I-ORG Veterinary__I-ORG Affairs__I-ORG at__O Hill's__B-LOC Pet__I-LOC nutrition__O stated;__O "Their__B-MISC research__O revealed__O that__O eicosapentaenoic__O acid__O ("EPA")__B-ORG was__O the__O most__O potent__O at__O reducing__O the__O breakdown__O signature__O seen__O in__O cartilage__O degradation.__O
These__O trials__O led__O directly__O to__O a__O successful__O patent__O filing__O in__O 2010__O (US2010/0261793A1,__B-ORG Method__I-ORG for__I-ORG Reducing__I-ORG Cartilage__I-ORG Damage__I-ORG in__O Dogs),__B-LOC in__O which__O both__O Harwood__B-PER and__O Caterson__B-PER were__O named3.6.__O
The__O aforementioned__O research,__O and__O by__O extension__O the__O patent,__O provided__O a__O verifiable__O foundation__O for__O Hill's__O to__O develop__O effective__O EPA__B-ORG dosages__O for__O dog__O food__O to__O be__O tested__O and__O brought__O to__O market.__O
It__O led__O directly__O to__O the__O company's__O development__O of__O new__O products__O containing__O specific__O ratios__O of__O EPA__B-ORG to__O the__O other__O constituent__O PUFA's.__B-ORG
Pet__O food__O products__O arising__O from__O this__O research__O are__O now__O marketed__O and__O sold__O by__O Hill's__B-MISC worldwide__O under__O the__O name__O Prescription__B-ORG Diet&#174;__I-ORG j/d__O food5.3.__O
The__O Hill's__B-ORG Pet__I-ORG Nutrition__I-ORG currently__O accounts__O for__O $2.16billion__O (13%)__O of__O Colgate-Palmolive's__B-ORG global__O net__O sales__O of__O $17__O billion5.3,__O 5.4.__O
Product__O sales__O are__O driven__O by__O a__O marketing__O campaign__O which__O specifically__O cites__O the__O research__O findings,__O viz__O "Hills&#174;__B-ORG Prescription__I-ORG Diet&#174;__I-ORG j/d&#174;__O helps__O your__O dog__O walk,__O run__O and__O jump__O more__O easily__O in__O just__O 21__O days"5.5.__O
New__O nutraceuticals__O The__B-ORG Cardiff__I-ORG team__O also__O has__O an__O on-going__O collaboration__O with__O Seven__B-MISC Seas__I-MISC (now__O owned__O by__O Merck,__B-ORG a__O Fortune__B-ORG 100__O company),__O which__O has__O included__O a__O successful__O preliminary__O clinical__O trial__O on__O the__O effects__O of__O omega-3__O PUFA's__B-ORG on__O joint__O cartilage5.6.__O
This__O collaboration__O has__O led,__O during__O the__O REF__B-ORG period,__O to__O the__O enhancement__O of__O existing__O products__O within__O the__O Seven__B-ORG Seas__I-ORG JointCare__I-ORG range__O (eg__O Jointcare__O Max,__O Supplex__O and__O Complete)__O for__O the__O alleviation__O of__O arthritis__O symptoms5.7.__O
Seven__O Seas__O acknowledges__O the__O contribution__O of__O Cardiff,__O which__O `provided__O scientific__O support__O for__O our__O existing__O omega-3__O supplements__O and__O helped__O in__O the__O development__O of__O additional__O product__O variants...[and]__O helped__O strengthen__O the__O credible__O scientific__O basis__O for__O our__O marketing__O activities__O in__O relation__O to__O omega-3__O PUFA__B-ORG based__O products.__O
In__O turn,__O this__O helped__O consolidate__O our__O position__O in__O the__O global__O marketplace'5.6.__O
The__O market__O value__O of__O dietary__O supplements__O in__O the__O UK__B-LOC was__O $1.1Billion__B-MISC in__O 2009__O and__O Seven__O Seas__B-MISC accounted__O for__O 6.5%__O of__O the__O market5.8.__O
Omega-3__O PUFA-containing__B-MISC products__O are__O currently__O worth__O about__O &#8364;13__O billion5.9__O globally.__O
Changing__O research__O practice__O The__O five__O neoepitope__O mAbs__O developed__O by__O Caterson__B-ORG and__O Hughes__B-ORG have__O been__O commercialised__O by__O Cardiff__B-ORG University__I-ORG through__O licensing__O and__O direct__O sales__O to__O three__O of__O the__O top__O 10__O pharmaceutical__O companies__O (Dupont,__B-ORG Hoechst,__I-ORG and__O Ely__B-PER Lilly).__I-PER
They__O are__O also__O marketed__O through__O five__O major__O antibody-__O reagent__O sales__O and__O distribution__O companies__O (Abcam,__B-ORG Novus__I-ORG Biologicals,__I-ORG Millipore,__I-ORG MD__I-ORG Biosciences__I-ORG and__I-ORG ThermoFisher)__I-ORG which__O has__O generated__O royalties__O to__O Cardiff__B-ORG University__I-ORG of__I-ORG &#163;85,000__I-ORG since__O 2008,__O reflecting__O sales__O of__O approximately__O &#163;450,000.__O
During__O the__O REF__B-MISC period__O the__O Cardiff__B-LOC team__O was__O involved__O in__O a__O Knowledge__B-ORG Transfer__I-ORG Partnership__I-ORG (KTP)__I-ORG with__O Obsidian__B-ORG Research__I-ORG Ltd.__I-ORG
This__O company__O is__O a__O nutraceuticals__O formulation__O manufacturer,__O based__O in__O South__B-MISC Wales,__I-MISC which__O develops__O its__O own__O range__O of__O products__O for__O the__O global__O market.__O
Since__O the__O KTP__B-ORG with__O Obsidian__O the__O company__O has__O adopted__O two__O scientific__O methods__O developed__O in__O Cardiff__B-ORG University__I-ORG to__O provide__O efficacy__O data__O for__O new__O formulations.__O
These__O methods__O are:__O in__O vitro__O experiments__O using__O bovine__O cartilage__O explants__O to__O analyse__O the__O efficacy__O of__O active__O ingredients__O (developed__O by__O Caterson__B-ORG and__O Hughes);__B-ORG lipid__O analyses:__O for__O the__O quality__O control__O of__O lipid__O based__O products__O (developed__O by__O Harwood).__B-ORG
The__O KTP__B-ORG associate__O trained__O four__O Obsidian__B-MISC employees__O so__O that__O all__O new__O products__O could__O be__O validated__O using__O these__O improved__O methodologies5.10.__O
